Uveal Melanoma

Pfeffer, Ulrich

doi:10.3390/cancers11121986

Cited by 1 publication

(1 citation statement)

References 56 publications

(73 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Uveal melanoma (UM) is the most common primary malignant intraocular tumor in adults; it has a very aggressive biologic and clinical behaviour, characterized by a remarkable capacity of hematogenous dissemination and metastasis [ 1 ].…”

Section: Introductionmentioning

confidence: 99%

Long-Term Maintained Response to Selective Internal Radiation Therapy in an Oligometastatic Uveal Melanoma Patient Treated with Concomitant Anti-PD-1 Therapy

Proietti¹,

Skroza²,

Filippi

et al. 2021

Life

View full text Add to dashboard Cite

Uveal melanoma (UM) is a primary neoplasm of the eye arising from the melanocytes residing in the iris, ciliary body or choroid. It is the most frequent intraocular malignancy and often determines metastases at distant sites, with a peculiar tropism for the liver. Metastatic UM has a poor prognosis, as any treatment affects the natural course of this fatal disease. Herein, we report a case of a UM metastatic to the liver in a 54 year-old female patient, initially treated with nivolumab without success. The patient was then scheduled for selective internal radiation therapy (SIRT) while continuing immunotherapy. This combination led to a complete and durable response and the patient is currently free of disease, two years after the diagnosis of the hepatic metastases. The association between SIRT and immunotherapy (IT) has very promising perspectives for metastatic UM, especially considering the disappointing or contradictory results of classic chemotherapies, IT alone and targeted therapies. Furthermore, this combination has been shown to have a good security profile. However, further studies are needed to confirm the efficacy of associating SIRT and IT and to clarify some unsolved problems, such as the timing of administration of these two therapies.

show abstract

Section: Introductionmentioning

confidence: 99%